Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Regeneus Ltd. ( (AU:CMB) ) has shared an announcement.
Cambium Bio Limited has received ethics approvals in both Australia and the United States to commence Phase 3 clinical trials for Elate Ocular®, a novel biologic eye drop for treating moderate to severe dry eye disease. These approvals represent a significant milestone in the company’s development pathway, enabling the initiation of a global Multi-Regional Clinical Trial program. The trials, set to begin patient dosing in October 2025, aim to support the registration of Elate Ocular® in major markets, with a Biologics License Application submission planned post-trial completion.
More about Regeneus Ltd.
Cambium Bio Limited is a Sydney-based clinical-stage regenerative medicine company specializing in innovative biologics for ophthalmology and tissue repair applications. The company leverages its proprietary technology based on human platelet lysate to develop a pipeline of novel therapeutics, with a primary focus on ophthalmology. Its lead product candidate, Elate Ocular®, targets unmet medical needs in dry eye disease treatment. Cambium Bio also applies its stem cell platform, Progenza™, to develop therapies for knee osteoarthritis and other tissue repair indications.
Average Trading Volume: 6,216
Technical Sentiment Signal: Sell
Current Market Cap: A$3.84M
Learn more about CMB stock on TipRanks’ Stock Analysis page.